Apogee Therapeutics, Common Stock Today
| APGE Stock | 58.43 5.48 10.35% |
Performance14 of 100
| Odds Of DistressLess than 22
|
Apogee Therapeutics, is trading at 58.43 as of the 22nd of September 2024, a 10.35 percent up since the beginning of the trading day. The stock's lowest day price was 52.96. Apogee Therapeutics, has about a 22 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. Equity ratings for Apogee Therapeutics, Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of August 2024 and ending today, the 22nd of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of July 2023 | Category Healthcare | Classification Health Care |
Apogee Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 43.19 M outstanding shares of which 8.28 M shares are presently shorted by private and institutional investors with about 23.52 trading days to cover. More on Apogee Therapeutics, Common
Moving together with Apogee Stock
| 0.71 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Apogee Stock
Apogee Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Michael MD | |||||||||||||||||||||||||||||||||||
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
| Apogee Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Apogee Therapeutics,'s financial leverage. It provides some insight into what part of Apogee Therapeutics,'s total assets is financed by creditors. | ||||||||||||||||||||||||||||||||||||
Apogee Therapeutics, Common (APGE) is traded on NASDAQ Exchange in USA. It is located in 221 Crescent Street, Waltham, MA, United States, 02453 and employs 91 people. Apogee Therapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.31 B. Apogee Therapeutics, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 43.19 M outstanding shares of which 8.28 M shares are presently shorted by private and institutional investors with about 23.52 trading days to cover.
Apogee Therapeutics, generates negative cash flow from operations
Check Apogee Therapeutics, Probability Of Bankruptcy
Ownership AllocationThe majority of Apogee Therapeutics, Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Apogee Therapeutics, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Apogee Therapeutics,. Please pay attention to any change in the institutional holdings of Apogee Therapeutics, Common as this could imply that something significant has changed or is about to change at the company.
Check Apogee Ownership Details
Apogee Therapeutics, Historical Income Statement
Apogee Stock Against Markets
Apogee Therapeutics, Corporate Management
| Carl MD | Chief Officer | Profile | |
| Noel Kurdi | Vice Relations | Profile | |
| Drew Badger | Senior Toxicology | Profile | |
| Monica Forbes | Senior Finance | Profile | |
| Matthew JD | General Counsel | Profile | |
| Jane Henderson | Chief Officer | Profile | |
| Dan Mulreany | Senior Strategy | Profile |
Already Invested in Apogee Therapeutics, Common?
The danger of trading Apogee Therapeutics, Common is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Apogee Therapeutics, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Apogee Therapeutics,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Apogee Therapeutics, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Information and Resources on Investing in Apogee Stock
When determining whether Apogee Therapeutics, is a strong investment it is important to analyze Apogee Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics,'s future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apogee Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apogee Therapeutics,. If investors know Apogee will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apogee Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Return On Assets (0.19) | Return On Equity (0.27) |
The market value of Apogee Therapeutics, is measured differently than its book value, which is the value of Apogee that is recorded on the company's balance sheet. Investors also form their own opinion of Apogee Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Apogee Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apogee Therapeutics,'s market value can be influenced by many factors that don't directly affect Apogee Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apogee Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Apogee Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apogee Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.